Diabetes: DexCom's Q4 prelims beat The Street, shares tick down anyway
DexCom's stock closes down a hair after it reports preliminary 4th-quarter sales numbers well ahead of Wall Street's expectations.
Dexcom Inc. shares closed down a hair today despite Wall Street-beating preliminary 4th-quarter sales numbers for the medical device company.
DexCom said it expects to report sales of roughly $51 million for the 3 months ended Dec. 31, 2013, a 61% surge over the same period last year and well ahead of the $46 million forecast on The Street. Full-year sales are pegged at $157 million, representing a 69% gain over 2012.
The results, released ahead of CEO Terry Gregg's presentation today at the J.P. Morgan Healthcare conference in San Francisco, were accompanied by product revenue guidance for fiscal 2014 of $205 million to $225 million, according to a regulatory filing.